Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.
Lars Hahn
Advertisement
Lars Hahn is senior vice-president, Global Sales Organization, at Vetter.
Articles by Lars Hahn
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals
4
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
5